Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bio-Thera Licenses Keytruda Biosimilar BAT3306 to Avalon for Middle East & North Africa

Fineline Cube Feb 4, 2026
Company Deals Drug

Akeso Licenses Yixining to Jumpcan for PCSK9 Promotion in China

Fineline Cube Feb 4, 2026
Company Deals

Grand Pharmaceutical to Acquire API Firms for RMB 316 Million

Fineline Cube Feb 4, 2026
Company Deals

Simcere Receives $40M Milestone from AbbVie for Trispecific Myeloma Drug

Fineline Cube Feb 4, 2026
Company Deals

Medtronic to Acquire CathWorks for $585M, Expand AI-Based FFRangio System

Fineline Cube Feb 4, 2026
Policy / Regulatory

NMPA Releases 101st Batch of Generic Reference Drugs

Fineline Cube Feb 2, 2026
Company Drug

Hualan Biological’s HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial

Fineline Cube Feb 4, 2026
Company Drug

Marubeni Launches Xenleta in China After Complex Licensing Journey

Fineline Cube Feb 4, 2026
Company Deals Digital

PingAn Good Doctor Partners to Establish Lifestyle Medicine

Fineline Cube Dec 21, 2022

China-based PingAn Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good Doctor,...

Company Deals

JW Therapeutics Collaborates with Juno for DLL3 CAR-T Therapy Development

Fineline Cube Dec 21, 2022

China-based JW Therapeutics Co., Ltd (HKG: 2126) has issued a stock exchange announcement revealing a...

Company Deals

Mabwell Bioscience Licenses Biosimilars to Russian Firm Binnopharm

Fineline Cube Dec 21, 2022

China-based Mabwell Bioscience (SHA: 688062) has announced the establishment of a licensing agreement with the...

Company Drug

Sirnaomics’ Lead Candidate STP707 Shows Promising Phase I Data

Fineline Cube Dec 21, 2022

Sino-US small interfering RNA (siRNA) specialist Sirnaomics (HKG: 2257) has revealed that its lead pipeline...

Company Drug

Kira Pharmaceuticals Gains NMPA and TGA Approvals for KP104 Phase II Study

Fineline Cube Dec 21, 2022

Sino-US biotech Kira Pharmaceuticals has announced receiving approvals from China’s National Medical Products Administration (NMPA)...

Company Deals

TowardPi Raises RMB 300 Million in Series C Financing Round

Fineline Cube Dec 20, 2022

China-based ophthalmology device maker TowardPi (Beijing) Medical Technology Ltd has reportedly raised close to RMB...

Company Drug

Aosaikang Receives FDA Approval for ASKG915 Clinical Trial

Fineline Cube Dec 20, 2022

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced receiving clinical trial approval for its...

Company Deals

Pfizer Exercises Option for Sisunatovir Rights with LianBio

Fineline Cube Dec 20, 2022

US major Pfizer Inc. (NYSE: PFE) has agreed with China-based LianBio (OTCMKTS: LIANY) to exercise...

Company Deals

Fosun Pharma Registers Comirnaty Vaccines in Hong Kong

Fineline Cube Dec 20, 2022

Shanghai Fosun Pharmaceutical Group Co (SHA: 600196) has announced that Comirnaty (BNT162b2) and Comirnaty bivalent...

Company Deals

XtalPi Partners with Singapore’s EDDC to Develop Lung Cancer Treatments

Fineline Cube Dec 20, 2022

Sino-US artificial intelligence (AI) firm XtalPi Inc. has struck a partnership with the Experimental Drug...

Deals

Prenetics Acquires Majority Stake in ACT Genomics to Boost Oncology Services

Fineline Cube Dec 20, 2022

Hong Kong-based Prenetics Global Ltd (NASDAQ: PRE) has announced the acquisition of a majority stake...

Company Drug

CStone’s Sugemalimab MAA Accepted by UK MHRA for NSCLC Treatment

Fineline Cube Dec 20, 2022

China-based CStone Pharmaceuticals (HKG: 2616) has announced that the Medicines and Healthcare products Regulatory Agency...

Company Drug

Ascletis Pharma Receives USPTO Notice for ASC10 Patent

Fineline Cube Dec 20, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) has announced receiving the Notice of Issuance from the...

Company Drug

HutchMed Initiates Rolling NDA Submission for Elunate to US FDA

Fineline Cube Dec 20, 2022

Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced the initiation of a rolling...

Legal / IP Policy / Regulatory

PCAOB Report Signals Relief for US-Listed Chinese Biotechs

Fineline Cube Dec 20, 2022

A report issued last week by the US Public Company Accounting Oversight Board (PCAOB) indicated...

Company Deals

Luye Pharma’s Shandong Boan Biotechnology IPOs on Hong Kong Stock Exchange

Fineline Cube Dec 19, 2022

China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary Shandong Boan Biotechnology Co., Ltd has officially...

Company Drug

Simcere Pharmaceutical Completes Enrollment for SIM0417 COVID-19 Drug Trial

Fineline Cube Dec 19, 2022

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the completion of enrollment of 1,208 patients...

Company Drug

Neurophth’s NFS-02 Gene Therapy Gets FDA IND Approval for LHON Treatment

Fineline Cube Dec 19, 2022

China-based gene therapy specialist Neurophth Biotechnology Ltd has announced obtaining Investigational New Drug (IND) approval...

Company Drug

TG ImmunoPharma Gains FDA Approval for Phase I Study of Anti-PVRIG Antibody

Fineline Cube Dec 19, 2022

China-based TG ImmunoPharma Co., Ltd has announced receiving the go-ahead from the US FDA to...

Company Deals Drug

Adagene Initiates International Study for ADG126 in Hepatocellular Carcinoma

Fineline Cube Dec 19, 2022

China-based biotech Adagene Inc. (NASDAQ: ADAG), which also operates out of San Diego, California, has...

Posts pagination

1 … 538 539 540 … 619

Recent updates

  • Merck Keytruda Revenue Drives $65.5B Sales Despite Gardasil China Slump
  • Hualan Biological’s HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial
  • Bio-Thera Licenses Keytruda Biosimilar BAT3306 to Avalon for Middle East & North Africa
  • Marubeni Launches Xenleta in China After Complex Licensing Journey
  • CMS-D017 Gets NMPA Approval for Complement-Mediated Kidney Disease Study
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Merck Keytruda Revenue Drives $65.5B Sales Despite Gardasil China Slump

Company Drug

Hualan Biological’s HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial

Company Deals

Bio-Thera Licenses Keytruda Biosimilar BAT3306 to Avalon for Middle East & North Africa

Company Drug

Marubeni Launches Xenleta in China After Complex Licensing Journey

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.